CG
VRTX icon

Cynosure Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Cynosure Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,079
Closed -$489K – 464
2025
Q4 		$489K Buy
1,079
+161
+18% +$69.4K 0.05% 197
2025
Q3 		$360K Hold
918
– – 0.04% 316
2025
Q2 		$409K Buy
918
+215
+31% +$99.1K 0.05% 271
2025
Q1 		$341K Sell
703
-60
-8% -$28K 0.05% 257
2024
Q4 		$307K Sell
763
-130
-15% -$60.3K 0.05% 211
2024
Q3 		$415K Sell
893
-643
-42% -$309K 0.06% 195
2024
Q2 		$720K Buy
1,536
+23
+2% +$9.98K 0.12% 125
2024
Q1 		$632K Buy
+1,513
New +$640K 0.11% 118

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Cynosure Group's VRTX Position: Q1 2026 in Review

Cynosure Group sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 1,079 shares — an estimated $489K sold.

Cynosure Group first reported a position in VRTX in Q1 2024 and held it in 8 quarters. The position peaked at $720K in Q2 2024. 1,688 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Cynosure Group reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Cynosure Group sold 1,079 Vertex Pharmaceuticals shares in Q1 2026, an estimated $489K.
  • Cynosure Group first reported a position in Vertex Pharmaceuticals in Q1 2024 and held it in 8 quarters.
  • Cynosure Group's Vertex Pharmaceuticals position peaked at $720K in Q2 2024.
  • 1,688 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Cynosure Group's 13F filing for Q1 2026, filed 14 May 2026.